Introduction
Cardiomyocytes react to neurohumoral stimuli and biomechanical stress during the processes that lead to adverse cardiac remodelling and heart failure (HF) via activation of pathways that induce pathological hypertrophy. Numerous investigators demonstrated that multiple genes are altered during pathological hypertrophy, such as differential gene expression, promoter modulation, or protein-protein interactions, and this pathological process is the result of the regulation of gene networks. [1] [2] [3] [4] [5] The molecular changes during the process of pathological hypertrophy resemble the changes during foetal cardiac development. Therefore, cardiac hypertrophy is often described as accompanied by the re-activation of a 'foetal gene programme'. [6] [7] [8] The re-activation of foetal genes in the adult failing heart is a complex biological process that involves transcriptional, post-transcriptional, and epigenetic regulation of the cardiac genome. Changes in this programme may be salutary adaptations to stress, but the aberrant expression of foetal genes involved in contractility, calcium handling, and myocardial energetics leads to maladaptive changes in cardiac function. Activation of the 'foetal gene programme' plays a causative role in adverse cardiac remodelling and the pathogenesis of HF in humans and mouse models. 9 However, the effects and precise mechanism of the activation of the 'foetal gene programme' in adult cardiac development and pathological hypertrophy are largely unknown.
Mesenchyme homeobox 1 (Meox1) is one gene in this gene network that is modulated on the transcriptional level and is part of the 'foetal gene programme ' . Studies indicated that mutations in Meox1, which encodes a transcription factor with a well-established role in somite development, caused a recessive Klippel-Feil syndrome (KFS) in mouse and human. [10] [11] [12] [13] [14] [15] Sun and colleagues confirmed that Meox1 is a critical molecular target that regulates breast cancer stem cells (BCSCs) and mesenchymal-like cell proliferation, and it may be a target for future drug development. 16 Some studies suggested a role for Meox1 in embryonic development, but Meox1 regulation of myocardial pathological hypertrophy is not known.
We recently found significantly increased Meox1 expression in heart tissues from hypertrophic cardiomyopathy (HCM) patients and adult mouse models, including familial dilated cardiomyopathy (FDCM) mice of the cTnT R141W strain, familial hypertrophic cardiomyopathy (FHCM) mice of the cTnT R92Q strain, and pressure overload-induced HF mice.
Therefore, the present study generated a cardiac-specific overexpression and knockdown transgenic mouse of Meox1 and elucidated the mechanism of Meox1 participation in pathological hypertrophy.
Methods
All mice used in this study were maintained on a C57BL/6 J genetic background and bred in an AAALAC-accredited facility. The Animal Care and Use Committees of the Institute of Laboratory Animal Science of Peking Union Medical College, China approved the animal protocol (ILAS-GC-2012-001). Tribromoethanol (216 mg/kg, i.p.) was used to anaesthetize mice during thoracic aorta constriction (TAC) surgery and echocardiography analysis, and the adequacy of anaesthesia was confirmed by the absence of a reflex response to foot squeeze. Mice were euthanized via cervical dislocation, and hearts were isolated for further histological, RNA, and protein analyses. All surgeries and subsequent analyses were performed in a blinded fashion. All procedures that involved human samples conformed to the principles outlined in the Declaration of Helsinki and were approved by the Ethics Committee of Fuwai Hospital, Beijing, China.
Human cardiac samples
Left ventricular interventricular septa were obtained from 18 patients with obstructive hypertrophic cardiomyopathy who underwent a Morrow septal myectomy. We excluded patients with myocardial infarction, congenital heart disease, congestive HF, and valvular heart diseases to minimize any potential confounding effects. Non-hypertrophic cardiac tissues were obtained from the same region of six healthy donors who died from an accident. The samples were immediately stored in liquid nitrogen until use. None of the donors had a history of cardiac disease. Written informed consent was obtained from all participants or their relatives.
Animals
The a-MHC-cTnT R92Q (referred as cTnT
R92Q
) FHCM transgenic mouse strain and a-MHC-cTnT R141W (referred as cTnT
R141W
) FDCM transgenic mouse strain were previously generated in our laboratory. [17] [18] [19] R92Q and R141W are the missense mutations in the strong tropomyosin-binding region of cardiac troponin T (cTnT). The cTnT R92Q mice manifest ventricular wall hypertrophy, and reduced ventricular chambers and diastolic dysfunction, which is a pathological phenotype that is similar to human HCM. [17] [18] 20 The cTnT R141W mice manifest dilated chambers, thin walls, and cardiac dysfunction, which is a pathological phenotype similar to human dilated cardiomyopathy. 19, 21 Genotyping of transgenic mice was performed using PCR. Full-length mouse Meox1 cDNA was cloned into an expression plasmid under the a-myosin heavy chain (a-MHC) promoter. The cardiac-specific Meox1-overexpressing transgenic mouse (referred as Meox1-ov) was generated via microinjection and genotyped using PCR. A 200 bp fragment of the transgenic gene was amplified for genotyping using 30 Figure S1A ). Loops for siRNA1 and siRNA2 were cloned in series into an expression plasmid under the a-MHC promoter. The cardiac-specific Meox1 knockdown transgenic mouse (referred to as Meox1-kd) was generated via microinjection and genotyped using PCR. A 400 bp fragment of the siRNA cassette was amplified for genotyping using 35 PCR cycles consisting of 94 C for 30 s, 58 C for 30 s, and 72 C for 30 s.
The Meox1-ov and Meox1-kd transgenic mice were crossed with the cTnT R92Q mice to generate a-MHC-cTnT
R92Q
ÂMeox1-ov double transgenic mice (referred to as DTG-ov) and a-MHCcTnT R92Q ÂMeox1-kd double transgenic mice (referred to as DTG-kd). The primer sequences in this section are given in the Supplementary material online, Table S1 .
TAC-induced cardiac hypertrophy mice model
Eight-to 10-week-old mice were used for the TAC surgery as previously described. 17 Briefly, Meox1-ov mice, Meox1-kd mice, and wild-type (WT) mice of the same age were anaesthetized via an i.p. injection of 216 mg/kg body weight tribromoethanol. The surgery was performed under passive respiration using a ventilator (125-150 times/min, Kent Scientific Torrington, CT, USA). The aorta was constricted between the origin of the right innominate and left common carotid arteries using a 6/0 polypropylene ligature and a blunted 27-gauge (0.41 mm OD) needle as a calibrator. Doppler analysis was performed to detect blood flow in the innominate artery (IA) and left common carotid artery (LCCA) 1 week after TAC. 22 Mice with an IA/LCCA flow ratio from 5.9 to 10.7 developed a comparable pressure gradient, and these mice were used in the present study. The sham procedure was identical to TAC except that the aorta was not ligated. Each surgical procedure was completed within 30 min to maintain body temperature at 37 C. An i.p. injection of 0.9% saline solution was administered to mice if dehydration occurred. All surviving mice were selected for follow-up experiments at 2, 4, or 8 weeks after surgery.
Survival analysis
The cumulative percentage mortality was calculated every month for Meox1-ov, Meox1-kd, and crossed mice, or calculated every 2 weeks for TAC-treated mice. Upon the death of each mouse, the body was autopsied by a pathologist, and morphological and pathological changes in the Meox1 accelerates hypertrophy decompensation heart were recorded. The Kaplan-Meier curves for survival analysis were compared using the log-rank test (SPSS 16.0 software).
Echocardiography
Echocardiography was performed with the small animal echocardiography analysis system (Vevo770, Canada) as previously described.
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Histological analysis
For light microscopy, cardiac tissue from mice was fixed in 4% formaldehyde and mounted in paraffin blocks, and sections were stained with haematoxylin and eosin (H&E) or Masson trichrome as previously described. [19] [20] [21] Measurement of myocyte cross-sectional area (CSA) and myocardial fibrosis were analysed by an observer blinded to the mouse genotypes using Aperio Image Scope v8.2.5 software.
RNA extraction, quantification, and real-time PCR
Total RNA was isolated from the heart tissues or collected cells using TRIzol Reagent (Invitrogen) as previously described. 19, 21 Briefly, firststrand cDNA was synthesized from 2 mg of total RNA using random primers and Superscript III reverse transcriptase according to the manufacturer's protocol (Invitrogen). The mRNA of ANP (natriuretic peptide type A), BNP (natriuretic peptide type B), Myh6 (myosin, heavy polypeptide 6, cardiac muscle, alpha), Tnnc1 (troponin C, cardiac/slow skeletal), Tnni3 (troponin I, cardiac 3), Myh7b (myosin, heavy chain 7B, cardiac muscle, beta), Gata4 (GATA-binding protein 4), Asb11 (ankyrin repeat and SOCS box-containing 11), Scd4 (stearoyl-coenzyme A desaturase 4), Pik3r1 (phosphatidylinositol 3-kinase, regulatory subnit, polypeptide 1), Bmp4 (bone morphogenetic protein 4), and Myo5b (myosin VB) were detected by real-time PCR using glyceraldeyde phosphate dehydrogenase (GAPDH) for normalization under standard conditions. Table S1 in the Supplementary material online shows the primer sequences in this section.
Protein extraction and immunoblotting
Total protein lysates from mouse heart were prepared as previously described. 19, 21 Briefly, after performing SDS-PAGE and transferring gels to nitrocellulose (Millipore), the membranes were incubated at 4 C overnight with antibodies against Meox1 (Abcam). After incubation with the appropriate secondary antibodies for 1 h at room temperature, antibody binding was detected with horseradish peroxidase (HRP)-conjugated immunoglobulin G (IgG; Santa Cruz) using a chemiluminescence detection system (Santa Cruz). Quantitative analysis of Meox1 protein used GAPDH as normalization, and bands were quantified using Image J software.
Constructs

Expression plasmids
The Meox1 overexpression plasmid (referred to as pMeox1) contained mouse Meox1 cDNA that was amplified using PCR (primer sequences are listed in Supplementary material online, Table S1 ) and cloned into the pcDNA3.1(þ) vector (Invitrogen) downstream of the cytomegalovirus (CMV) promoter. The presence of the insert was verified using restriction digestion and DNA sequencing. The Meox1 knockdown plasmid, pcDNA TM 6.2-GW/EmGFP-miR1 þ 2, was established and described in the animal section of Section 2.
Reporter plasmids
The genomic sequence located between -5409 bp and -384 bp upstream of the ATG was amplified using PCR, with introduced KpnI and XhoI restriction sites, respectively (primer sequences are listed in Supplementary material online, Table S1 ). The PCR product was cloned into the pGL3-Basic vector (Promega) with the firefly luciferase gene as the reporter. The pRL-CMV vector (Promega) containing the reporter Renilla luciferase gene upstream of the CMV promoter was used to normalize the transfection efficiency between different experiments. pGFP codes for green fluorescent protein (GFP), which was used to monitor the transfection efficiency in chromatin immunoprecipitation (ChIP) assays.
Cell culture and norepinephrine (NE) treatment
HL-1 adult mouse cardiac muscle cells were maintained in Claycomb medium (Sigma) supplemented with 4 mM L-glutamine, 100 lM penicillin and streptomycin, 50 lM NE, and 10% foetal calf serum (FCS) as previously described. 23 The medium was changed approximately every 48 h.
Cells were grown at 37 C in 5% CO 2 and 95% air. HL-1 cells were transfected with the pMeox1 or Meox1 knockdown plasmid using ViaFect TM transfection reagent (Promega) according to the manufacturer's instructions. Stable cell lines were established via subsequent selection with 800 lg/mL G418 or 5 lg/mL blasticidin (Sigma). HL-1 cells were switched to a medium without NE (MedChem Express) 5 days prior to experimentation and starved in a serum-free medium for at least 24 h before treatment. Cell lines were treated for 24 h with NE (75 lM), and cells were harvested for real-time PCR or immunofluorescence analyses.
Immunofluorescence
Sections of hearts were prepared using a standard pathological procedure as previously described. 24 Briefly, sections were dewaxed and rehydrated. The epitope was unmasked, and sections were blocked and incubated with an anti-Meox1 antibody (Abcam) overnight at 4 C.
Sections were washed with phosphate-buffered saline (PBS) and incubated with Alexa 488-conjugated goat anti-rabbit IgG (Invitrogen, USA) for 1 h at room temperature. HL-1 cells were cultured as described above and prepared using a standard procedure as previously described. 25 The slides were incubated with an actin antibody (Abcam) overnight at 4 C. Sections were washed with PBS and incubated with Alexa 488-conjugated goat anti-mouse IgG (Invitrogen) for 1 h at room temperature. All slides were counterstained with 300 nM 4 0 ,6-diamidino-2-phenylindole (DAPI; Invitrogen). Sections were washed with PBS and mounted in ProLong Gold anti-fade reagent (Invitrogen). Images of the sections were collected and analysed under a confocal laser scanning microscopy (Leica TCS SP2, Germany).
Digital gene expression profiling
Total RNA was isolated from heart tissues using TRIzol Reagent as described above. Digital gene expression (DGE) library preparation, Illumina RNA sequencing, and data processing were performed as described previously, 26 and the library preparations were sequenced on an Illumina HiSeq 2500 platform. 
Transient transfections and luciferase assays
HL-1 cells were plated in 6-well plates and cultured as described above. DNA was transfected using ViaFect TM transfection reagent according to the manufacturer's instructions when the cells reached $35% confluence. In each experiment, 0.5 lg of firefly reporter plasmid was cotransfected with different amounts of pMeox1. The total amount of transfected DNA was made equal in each experiment using pcDNA3. In addition, 0.02 mg of the pRL-CMV vector was always co-transfected for normalization. Cells were harvested 40 h after transfection, when the cells reached $100% confluence, and luciferase activities were assayed using the Dual-Luciferase system (Promega) according to the manufacturer's instructions. The firefly luciferase activity in each sample was normalized to Renilla luciferase to correct for variations in transfection efficiency.
Chromatin immunoprecipitation assay
HL-1 cells were plated on 60 mm dishes and transfected using ViaFect TM transfection reagent with either 3 mg of pMeox1 or 3 mg of pcDNA3 as a control. The p5.0GATA4-luc plasmid (1.5 mg) was co-transfected when indicated. In all cases, 0.3 mg of the pGFP plasmid encoding GFP was included to monitor the transfection efficiency. Cells were cross-linked with 1% formaldehyde for 10 min at 42 h after transfection, when the cells reached $100% confluence, and lysed in buffer containing a protease inhibitor cocktail. Chromatin extraction and immunoprecipitations were performed according to the Merck Millipore protocol for ChIP. Briefly, chromatin was fragmented via sonication and pre-cleared using a salmon sperm DNA-protein A-agarose 50% slurry for 2 h at 4 C.
Immunoprecipitation was performed via incubation with a goat polyclonal anti-Meox1 antibody (Santa Cruz) or normal mouse IgG (Abcam) at 4 C overnight. The immune complexes were washed, and the cross-link was reverted. DNA fragments were extracted using phenol/chloroform and precipitated with ethanol. A fragment of the GATA4 promoter and an unrelated genomic region of the GAPDH gene that was used as negative control were amplified using PCR (primer sequences are listed in Supplementary material online, Table S1 ).
Gata4 knockdown
Four Gata4 shRNAs (Gata4-shRNAs) in a pGFP-C-shLenti vector under the U6 promoter were purchased from ORIGENE, and HL-1 cells were transfected according to the manufacturer's protocol. Stable cell lines were established by subsequent selection with 1.0 lg/mL puromycin (Sigma), and Gata4 mRNA expression was detected using real-time PCR. Selected cell lines were cultured and harvested for real-time PCR or immunofluorescence analysis.
Statistical analysis
The data were analysed with unpaired two-tailed Student's t-tests for two groups, one-way analysis of variance (ANOVA) with Tukey correction for multiple groups, or nested ANOVA for analysis of myocyte CSA and collagen area. The data were expressed as the means ± SD from individual experiments. The differences were considered to be significant at P < 0.05.
Results
Meox1 is expressed in cardiomyocytes and induced under cardiomyopathy and HF
To identify the location of expressed Meox1 protein in cardiomyocytes, we stained heart tissue sections from WT mice at 2 weeks of age.
Immunofluorescence analysis revealed that Meox1 localized primarily in the nucleolus of cardiomyocytes, with small quantities in the cytoplasm ( Figure 1A ; see Supplementary material online, Figure S1B ). Then we examined Meox1 expression characteristics over time and found that Meox1 was strongly expressed in the hearts of WT mice at post-natal day 0, and Meox1 expression obviously decreased thereafter with age ( Figure 1B and C) .
Notably, compared with the decreased Meox1 expression in adults hearts, Meox1 expression was increased significantly in FDCM cTnT R141W mice, FHCM cTnT R92Q mice, and pressure overloadinduced (TAC treatment) HF mice [ Figure 1D and E; n = 6 mice per group, P < 0.01 or P < 0.001 vs. non-transgenic (NTG) littermates]. Meanwhile, we found that the transcript abundance showed a similar tendency to the protein level of Meox1 (see Supplementary material online, Figure S1C ). Immediately afterwards, we examined Meox1 expression in HCM patients and healthy heart donors, and Meox1 expression similarly increased significantly under HCM in human heart tissues ( Figure 1F and G, n = 6 in normal and n = 18 in HCM patients, P < 0.001 vs. normal). This change in Meox1 is part of the so-called foetal-like gene expression reprogramming, and this phenomenon prompted us to investigate further the role of Meox1 in cardiomyopathy and HF pathogenesis.
Meox1 accelerates morphology breakage and cardiac functional decompensation in FHCM mice
In view of the results on Meox1 expression, we generated cardiacspecific Meox1 overexpression and knockdown transgenic mice ( Figure  2A and B) . Two lines of Meox1-ov mice and two lines of Meox1-kd mice were selected from the 55 and 22 founders, respectively. The selected lines were analysed using M-mode echocardiography, and both the Meox1-ov mouse lines demonstrated thick-walled ventricles and larger left ventricular diameters (see Supplementary material online, Table S2 ) compared with the NTG group. The two lines of Meox1-kd mice exhibited opposite phenotypes from the Meox1-ov mice (see Supplementary material online, Table S3 ).
We mated one of the two lines from Meox1-ov or Meox1-kd mice with the cTnT R92Q mice as described in the Methods section to investigate the role of Meox1 in FHCM pathogenesis. Meox1 expression in these six groups was detected using western blot ( Figure 2C and D, n = 6 mice per group, P < 0.05 or P < 0.001 vs. NTG; P < 0.01 or P < 0.001 vs. cTnT
R92Q
). Cumulative mouse mortality data from all groups were recorded from 1 to 10 months of age ( Figure 2E) , and remodelling and mural thrombi were observed in mouse hearts in post-mortem examinations. The survival rate was 100% in the NTG group (n = 44), but it was only 87.2% in the cTnT R92Q group (n = 39, P < 0.05 vs. the NTG group) until 10 months of age. However, the survival rate further decreased by 26.1% in the DTG-ov group (n = 18, P < 0.05 vs. the cTnT R92Q group).
Transgenic overexpression of Meox1 decreased, while Meox1 knockdown increased, the survival rate of cTnT R92Q mice. We analysed cardiac function and geometry using M-mode echocardiography in all six groups at 1, 3, 5, 7, and 10 months of age to confirm the impairment by Meox1 of FHCM. The cTnT R92Q mice exhibited typical FHCM phenotypes with smaller chambers, thick walls, myocyte disarray, and interstitial fibrosis. [17] [18] 20 However, the FHCM geometry phenotypes were significantly exacerbated because of the transgenic overexpression of Meox1 in the cTnT R92Q mice, which was demon- Tables S4-S8 show the echocardiographic parameters of LVEDD, LV diameter at endsystole (LVESD), LVPWD, LV posterior wall thickness at end-systole (LVPWS), LVFS, and SV in these six groups at 1, 3, 5, 7, and 10 months of age.
Therefore, the pathological process in cTnT R92Q mice may be accelerated from the compensation stage to the decompensation stage with Meox1 overexpression in heart tissues.
Meox1 accelerates cardiac pathological changes in FHCM mice
We found that the geometric morphology and functional changes were accelerated into the decompensation stage in DTG-ov mice because of Meox1 overexpression. Therefore, we examined pathological changes in cTnT R92Q FHCM mice with Meox1 overexpression or knockdown.
Hearts from all six groups were sampled for gross morphology and examination of histological and hypertrophic markers at 7 months of age, during the decompensation stage of DTG-ov mice. Histopathological changes of thick wall, small chamber, myocyte disarray, and interstitial fibrosis in cTnT R92Q mice were significantly accelerated from the compensation stage into the decompensation stage because of the transgenic overexpression of Meox1, which was demonstrated using H&E stain for gross morphology and myocardial microstructure. Wall thickness declined rapidly, and the state of myocyte disarray deteriorated in DTG-ov mice compared with the cTnT R92Q mice ( Figure 3A , and TAC mice models. (E) Quantitative analysis of Meox1 expression using GAPDH for normalization (n = 6 mice per group, **P < 0.01 or ***P < 0.001 vs. NTG littermates). (F) Meox1 expression in heart tissues from HCM patients and normal controls. (G) Quantitative analysis of Meox1 expression using GAPDH for normalization (n = 6 hearts in normal control and n = 18 hearts in HCM patients, ***P < 0.001 vs. normal control).
.
cardiomyocytes per mouse, P < 0.05 vs. NTG; P < 0.05 vs. cTnT R92Q ), although the size of whole hearts was larger in the DTG-ov mice than in the cTnT R92Q mice. While the heart weight (HW)/body weight (BW) ratio remain unchanged as a result of the greatly decreased wall thickness ( Figure 3D , P < 0.05 vs. NTG; P < 0.05 vs. cTnT R92Q ), this ratio clearly improved with Meox1 knockdown in the DTG-kd mice ( Figure  3C and D, P < 0.05 vs. cTnT R92Q ). Moreover, malalignment and collagen accumulation in the interstitial space prominently increased in the DTGov mice because of Meox1 overexpression ( Figure 3B , E, and F, P < 0.001 vs. NTG; P < 0.01 vs. cTnT R92Q ). Therefore, the DTG-ov mice exhibited the typical decompensation stage from 7 months of age. Furthermore, we examined the hypertrophic molecular markers, ANP and BNP, using real-time PCR and found that the expression of these markers increased with Meox1 overexpression, while it decreased with Meox1 knockdown in the DTG mice compared with the cTnT R92Q mice ( Figure 3G and H, n = 6 mice per group, P < 0.05 vs. NTG; P < 0.05 vs. cTnT R92Q ). Taken together, examination of echocardiographic, histopathological, and hypertrophic molecular marker expression consistently demonstrated that Meox1 overexpression exacerbated, while Meox1 knockdown improved, the pathological phenotypes of FHCM in mice.
Meox1 enhances susceptibility to HF in response to pathological stress of pressure overload
As we observed above, Meox1 overexpression accelerated, while Meox1 knockdown inhibited, the decompensation process of FHCM. However, the effects of Meox1 under pathological stress of pressure overload were not known. The TAC treatment model of cardiac hypertrophy and HF mimics pressure overload stimulation. 17 Therefore, we then subjected WT, Meox1-ov, and Meox1-kd mice to pressure overload via TAC treatment. Death occurred from the second week after TAC treatment in the Meox1-ov mice, which was 2 weeks earlier than in WT mice. The survival rate was only 64.3% in the Meox1-ov-TAC group, which was an 11.4% decline compared with the WT-TAC group [ Figure 4A Tables S9-S11 show the echocardiographic parameters of LVEDD, LVESD, LVPWD, LVPWS, LVFS, and SV in these six groups at 2, 4, and 8 weeks after TAC treatment.
Gross morphology from histopathological examination of these three groups after TAC treatment was consistent with the echocardiography analyses ( Figure 4G-I) . Furthermore, the misalignment and collagen accumulation in the interstitial space increased prominently in the Meox1-ov-TAC mice compared with the WT-TAC group ( Figure 4J and K, n = 3 independent experiments, P < 0.001 vs. WT-sham; P < 0.05 vs. WT-TAC). Therefore, the Meox1-ov mice entered the typical decompensation stage at the eighth week after TAC, and Meox1-kd mice manifested an opposite phenotype ( Figure 4G-K) . Changes in myocyte sizes were consistent with the gross morphology in these three groups ( Figure 4L , n = 3 mice per group and n = 30-40 cardiomyocytes per mouse, P < 0.05 vs. WT-sham, P < 0.05 vs. WT-TAC). Furthermore, we also examined the hypertrophic markers ANP and BNP, and found that the expression of these markers was elevated in Meox1-ov-TAC mice and decreased in Meox1-kd-TAC mice compared with WT-TAC mice ( Figure 4M and N, n = 6 mice per group, P < 0.05 or P < 0.01 vs. WT-sham; P < 0.05 vs. WT-TAC). Collectively, these data indicated that Meox1 overexpression directly impaired cardiac function and accelerated the pathological process of pressure overload-induced cardiac hypertrophy and HF.
In addition, we also investigated Meox1 modulation in an adriamycin (ADR)-induced cardiomyopathy/HF mouse model. 19, 21 We found that Meox1 overexpression accelerated, while Meox1 knockdown improved, the pathological processes of cardiomyopathy/HF using survival analysis and echocardiography examination (see Supplementary material online, Figure S2A -E, Table S2 ).
Gata4 is a downstream target of Meox1
DGE profiling analysis was performed on the heart tissues from Meox1-ov and Meox1-kd mice and their NTG littermates at 3 months of age to examine the downstream targets of Meox1. More than 100 genes were screened out, whose level directly correlated with Meox1 expression 
( Figure 5A ). Seven genes, Myh7b, Gata4, Asb11, Scd4, Pik3rl, Bmp4, and Myo5b, were selected based on the results of DGE profiling and realtime PCR ( Figure 5B, P < 0.05 or P < 0.01 vs. NTG mice). Subsequently, functional research reports and bioinformatics analysis, including a search for the presence of putative transcription factor-binding sites in the 5 0 -flanking region and part of the first and/or second exon and the Meox1-binding sequence, were determined for these genes, and Gata4 was screened out. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] We next examined whether Meox1 activated Gata4 gene expression using transient transfection assays to determine whether the Meox1 gene maintained Gata4 expression via direct activation of transcription or the activity of intermediate regulators. We then used plasmid p5.0Gata4-luc, which contained a fragment of $5.0 kb of the mouse Gata4 promoter, followed by the luciferase reporter gene and Meox1 overexpression plasmid ( Figure 5C ). pMeox1 induced a dose-dependent activation of the Gata4 promoter, and this transactivation effect of Meox1 was specific for Gata4 regulatory sequences because Meox1 did not activate the control vector pGL3-Basic, which is a reporter vector containing a CMV promoter upstream of the luciferase gene ( Figure 5D , n = 4 independent experiments). We co-transfected pMeox1 with the p5.0Gata4-luc plasmid and, after immunoprecipitation of the crosslinked material with an anti-Meox1 antibody and PCR with specific primers, we obtained a band corresponding to sequences of the mouse Gata4 gene (Figure 5E ), which indicated that Meox1 was bound to the mouse Gata4 promoter, and the quantitative analysis was shown in Supplementary material online, Figure S2F . The HW to BW ratio was determined for WT-sham (n = 6), WT-TAC (n = 6), Meox1-ov-sham (n = 6), Meox1-ov-TAC (n = 6), Meox1-kd-sham (n = 6), and Meox1-kd-TAC (n = 6) mice (*P < 0.05 vs. NTG, NS: not significant). H&E staining of the whole-heart transverse sections from WT, Meox1-ov, and Meox1-kd groups at the 8th week after sham (G) or TAC treatment (H) 
3.6
Knockdown of GATA4 ameliorated morphological and functional changes in a Meox1 cell line with NE stimulation HL-1 cardiomyocytes were transfected with empty vector as control, a Meox1 overexpression plasmid, or a Meox1 knockdown plasmid. The hypertrophic response was determined, and Meox1 overexpression significantly increased cell size of HL-1 ( Figure 6A and B, n = 3 independent experiments, n = 30-40 cardiomyocytes per group, P < 0.05 vs. control group) and up-regulated ANF, BNP, cTnI, cTnC, and Myh6 mRNA expression ( Figure 6C -G, P < 0.05 vs. the control group), which were all target genes of Gata4, while ANP and BNP are also classical hypertrophic markers of hypertrophy. The effects of Meox1 on hypertrophic response were investigated under the pathological stimulation of NE. We found that Meox1 increased susceptibility to NE treatment compared with the control group, as demonstrated by cell size and the expression of hypertrophic markers. These results are consistent with the results in vivo, and Meox1 knockdown exhibited an opposite phenotype ( Figure 6A -G, P < 0.05 or P < 0.01 vs. The control group).
We observed changes in Meox1 regulation of cardiac morphology and hypertrophic markers in HL-1 cells after Gata4 knockdown to determine whether Meox1 accelerated myocardial hypertrophic decompensation via a downstream target, Gata4, at least in part. Vectors of lentiviral shRNA were transfected into HL-1 cells and verified using real-time PCR, and the level of Gata4 mRNA decreased to 83.4, 63.5, 68.0, and 62.5% with Gata4-shRNA1-4, respectively (Supplementary material online, Figure S2G ). We selected Gata4-shRNA1 in subsequent experiments. We found that Gata4 knockdown abolished the NEinduced increase in cell size and the up-regulation of mRNA expression of the hypertrophic markers ANP and BNP in the Meox1 expression group (Figure 6A-D, P < 0.05 vs. the control group). Collectively, these data indicated that Meox1 accelerated the myocardial hypertrophic process via the downstream target, Gata4, at least in part, in HL-1 cells.
Discussion
HF is a common end-stage of many major cardiac diseases, which represents the primary cause of hospitalization and death worldwide. Hypertrophic remodelling is a common observable process in numerous types of heart diseases, including ischaemic diseases, hypertension, aortic stenosis, valvular dysfunctions, and genetic forms of cardiomyopathies. Sustained pathological hypertrophy remains the major clinical predictor of HF and sudden cardiac death in humans. [37] [38] [39] Greater insight into the molecular mechanisms underlying the pathogenesis of this disease is a prerequisite for the design of pharmacotherapeutic strategies. Many foetal genes are re-activated in the adult failing heart, which activate the processes involved in pathological cardiac remodelling. The re-activation Tables S2-S8) . Then, we investigated the modulation of Meox1 in induced models. Data indicated that Meox1 overexpression directly impaired cardiac function and accelerated the pathological process of pressure overload-induced cardiac hypertrophy and HF (Figure 4 ; see Supplementary material online, Tables S8-S11 ). In addition, we also investigated Meox1 modulation in an ADR-induced cardiomyopathy/HF mouse model and found that Meox1 overexpression accelerated, and Meox1 knockdown improved, the pathological process of cardiomyopathy/HF using survival analysis and echocardiography examination (see Supplementary material online, Figure S1B -F, Table S12 ).
In sum, Meox1 accelerated hypertrophy decompensation in vivo, and we elucidated the mechanism of the participation of Meox1 in this pathological process. DGE profiling indicated that >100 genes were altered and that these levels directly correlated with Meox1 expression CSA of myocytes for three groups with NE treatment or shGata4 transfection (n = 3 independent experiments and n = 30-40 cardiomyocytes per group, *P < 0.05 or **P < 0.01 vs. control group). Quantitative analysis of ANP (C), BNP (D), cTnI (E), cTnC (F), and Myh6 (G) was carried out using real-time PCR in three groups with NE treatment or Gata4-shRNA transfection (n = 3 independent experiments, *P < 0.05 vs. control group, ns: not significant).
Meox1 accelerates hypertrophy decompensation ( Figure 5A) . Subsequently, seven genes, Myh7b, Gata4, Asb11, Scd4, Pik3rl, Bmp4, and Myo5b, were first selected using real-time PCR confirmation ( Figure 5B), and Gata4 was selected according to functional research reports and bioinformatics analysis. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Finally, promoter activity and ChIP and Gata4 knockdown analyses were used ( Figures 5D and E, and 6), and the data indicated that Meox1 directly accelerated the myocardial hypertrophic process via the downstream target Gata4, at least in part. Pathological hypertrophy at the cellular level is primarily regarded as the response of cardiomyocytes to biomechanical stress, including pressure or volume overload, reactive oxygen species, cytokines, and circulating neurohormones, which activate an intrinsic web of interconnected signalling modules within cardiomyocytes. Many of the stress signalling pathways culminate in the nucleus with activation of a set of transcription factors and co-regulators, which leads to alterations in cardiac gene expression. 42, 43 In addition to its role in maintaining differentiated gene expression in the post-natal/adult heart, Gata4 also mediates inducible gene expression in response to hypertrophic stimuli, and it is specialized to regulate adaptive and maladaptive growth. 30, 32, [44] [45] [46] To date, various reports support the hypothesis that Gata4 functions as a transcriptional convergence point in the adult heart whereby multiple stress signals alter Gata4 which modifies the cardiac hypertrophic response or the survival of individual myocytes. Therefore, Meox1 interacts with this transcriptional convergence point, Gata4, at least in part; moreover, multiple regulation pathways were altered in the modulation of Meox1 in hypertrophic decompensation. Recently, it was suggested that Meox1 may be a target for future drug development in cancer. 16 Molecular markers that track the foetal gene programme may serve as useful clinical biomarkers of pathological hypertrophy or HF progression. Indeed, circulating NT-proBNP is a standard biomarker in this area. 47 Therefore, Meox1 may become a potential biomarker or target for therapies aimed at pathological hypertrophy or HF. Taken together, Meox1 and other foetal programme genes independently act at a different level of gene regulation, and together these genes form a highly interconnected network. These gene networks offer multiple therapeutic entry points to suppress the aberrant expression of foetal genes and adverse remodelling processes of the failing heart.
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